Prevention of influenza in at-risk children: Vaccination is best

Prescrire International

Volumn 16, Issue 87, 2007, Pages 9-11

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; OSELTAMIVIR; PLACEBO; ZANAMIVIR; INFLUENZA VACCINE;

ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; BEHAVIOR DISORDER; BIRTH DEFECT; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; CONFUSION; CYSTIC FIBROSIS; DELIRIUM; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN UNION; FLU LIKE SYNDROME; HALLUCINATION; HUMAN; INCIDENCE; INFLUENZA; META ANALYSIS; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; SEIZURE; SINGLE DRUG DOSE; SKIN DISEASE; SUICIDE; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS RESISTANCE; VIRUS STRAIN; VOMITING; DRUG APPROVAL; DRUG RESISTANCE; EUROPE;

AMANTADINE; ANTIVIRAL AGENTS; CHILD; DRUG APPROVAL; DRUG RESISTANCE; EUROPE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; OSELTAMIVIR; VACCINATION; ZANAMIVIR;

EID: 33847742172     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Prescrire Editorial Staff "Antiviral drugs in influenza" Prescrire Int 2006; 15 (81): 21-30.
2. Prescrire Rédaction "Vacciner les enfants contre la grippe? Seulement en cas de risque élevé de complication grave" Rev Prescrire 2003; 23 (245): 852-856.
3. Turner D et al. "Systematic review and economic decision modelling for the prevention and treatment of influenza A and B" Health Technol Assess 2003: 7 (35): 286 pages.
4. U.S. Food and Drug Administration "Prescribing information - Relenza°" March 2006: 16 pages.
5. European Medicines Agency - CHMP "European Public Assessment Report (rev. 3) - Tamiflu - Scientific discussion" 23 pages; posted on the EMEA website on 12 April 2006.
6. Hayden FG et al. "Management of influenza in households: a prospective, randomised comparison of oseltamivir treatment with or without post-exposure prophylaxis" J Infect Dis 2004, 189: 440-449.
7. Prescrire Editorial Staff "Oseltamivir: cutaneous and ocular adverse effects in children" Prescrire Int 2006; 15 (85): 182-183.
8. European Medicines Agency "Procedural steps taken and scientific information after the authorsation - Tamiflu" EMEA website accessed 20 July 2006: 1 page.
9. U.S. Department of Health and Human Services "CDC health alert - CDC recommends against the use of amantadine and rimantadine for the treatment or prophylaxis of influenza in the United States during the 2005-06 influenza season" 14 January 2006. Website http://www.fda.gov accessed 12 March 2006.
10. Bright RA et al. "Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States" JAMA 2006; 295 (8): 891-894.
11. French Institut de veille sarritaire "La surveillance épidémilologique de la grippe en France: renforcement des systèmes de surveillance. Bilan de la saison grippale 2004-2005" December 2005: 41 pages.
12. "EU approvals for GSICs Relenza in prevention of flu" Press release by APM Health Europe on 24 August 2006: 1 page.
13. Prescrire Rédaction "Épizootie de grippe aviaire" Rev Prescrire 2006; 26 (271): 294-295.
14. Haute autorité de santé - Commission de la transparence "Avis de la Commission - Tamiflu" 21 June 2006: 9 pages.